EZH2 in cancer progression and potential application in cancer therapy: A friend or foe?

Ke Sin Yan, Chia Yuan Lin, Tan Wei Liao, Cheng Ming Peng, Shou Chun Lee, Yi Jui Liu, Wing P. Chan, Ruey Hwang Chou

Research output: Contribution to journalReview articlepeer-review

62 Citations (Scopus)


Enhancer of zeste homolog 2 (EZH2), a histone methyltransferase, catalyzes trimethylation of histone H3 at Lys 27 (H3K27me3) to regulate gene expression through epigenetic machinery. EZH2 functions as a double-facet molecule in regulation of gene expression via repression or activation mechanisms, depending on the different cellular contexts. EZH2 interacts with both histone and non-histone proteins to modulate diverse physiological functions including cancer progression and malignancy. In this review article, we focused on the updated information regarding microRNAs (miRNAs) and long non coding RNAs (lncRNAs) in regulation of EZH2, the oncogenic and tumor suppressive roles of EZH2 in cancer progression and malignancy, as well as current pre-clinical and clinical trials of EZH2 inhibitors.

Original languageEnglish
Article number1172
JournalInternational Journal of Molecular Sciences
Issue number6
Publication statusPublished - Jun 1 2017


  • Cancer
  • Epigenetic regulation
  • EZH2
  • EZH2 inhibitors
  • lncRNAs
  • microRNAs

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Computer Science Applications
  • Spectroscopy
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry


Dive into the research topics of 'EZH2 in cancer progression and potential application in cancer therapy: A friend or foe?'. Together they form a unique fingerprint.

Cite this